GSK-201928

Study Sponsor: GSK

Study Title

A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).

Medicine or Vaccine (generic name)

nemiralisib

Sponsor Identification Number

201928

Trial Registry Identification Number(#'s)

NCT02522299

Medical Condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=201928

Link to study details on ClinicalTrials.gov (if available)

https://www.clinicaltrials.gov/ct2/show/NCT02522299

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003696-30

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

The raw data are included within the analysis-ready data for this study and are not provided separately

Date Added to this Site

July 2021